Key result
Short-term treatment with acipimox reduced free fatty acid concentrations but did not improve endothelial-dependent flow-mediated dilation in individuals with metabolic syndrome (P=0.42).
Why the study?
Elevated free fatty acid concentrations contribute to impaired vascular function in insulin resistance, prompting the hypothesis that lowering FFA with acipimox would improve endothelial function in metabolic syndrome.
Does acipimox improve endothelial function measured by flow-mediated dilation in individuals with metabolic syndrome?
Population
18 participants with metabolic syndrome and 17 healthy controls
Comparison
Acipimox 250 mg orally every 6 hours vs placebo
Design
Randomized, double-blind, crossover trial
Follow-up
7 days
Authors
Loading...
Acipimox does not improve FMD despite lowering free fatty acids; challenges acute FFA reduction as a strategy to restore endothelial function in metabolic syndrome.
RCT (n=35)
Double-blind
crossover
Does acipimox improve endothelial function measured by flow-mediated dilation in individuals with metabolic syndrome?
p-value: p=0.42
Short-term reduction of free fatty acids with acipimox successfully lowers FFA levels but does not improve endothelial function in patients with metabolic syndrome.
Aday et al. (2019) conducted an RCT in Metabolic syndrome (n=35). Acipimox vs. Placebo was evaluated on Endothelial function measured by flow-mediated dilation (FMD) (p=0.42). Short-term treatment with acipimox reduced free fatty acid concentrations but did not improve endothelial-dependent flow-mediated dilation in individuals with metabolic syndrome (P=0.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: